Takeaway
- Ixekizumab is associated with clinical improvement and a low discontinuation rate in patients with moderate to severe psoriasis, according to a retrospective study.
Key results
- Ixekizumab was associated with significant improvements in Psoriasis Area and Severity Index (PASI) score at 4, 12, and 24 weeks (P<.001 for all).
- Improvements were also observed at the same times in the subgroup of patients with psoriatic arthritis when analysed by the Disease Activity 28 score (P<.001 for all).
- At 24 weeks, 90% of patients had achieved ≥75% improvement in PASI score (PASI 75), whereas 72% had achieved PASI 90 and 57% had achieved PASI 100.
- 2% of patients discontinued because of adverse events.
Study design
- 110 patients with moderate to severe psoriasis who completed at least 24 weeks of ixekizumab treatment were included.
- Funding: None.
Limitations
- Retrospective study.
- Small patient sample size.
References
References